CD274 and lung carcinoma: Moreover, Herbst et al. [33] reported that anti-PD-L1 therapy produced significant responses, particularly in cancer patients with high levels of PD-L1 and infiltrating immune cells—suggesting that the degree of immune cell infiltration may be related to the efficacy of anti-PD-L1 therapy in lung cancer patients.